Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 24, 2005. The report details a share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests regarding the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share repurchase:
- Shares Purchased: 790,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,258.4132 pence per share.
- Treasury Holdings: 74,708,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,864,906,545 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 790,000 shares on February 24, 2005. Additionally, the GlaxoSmithKline Employee Trust transferred 7,878 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on February 23, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 790,000 share repurchase based on the disclosed price of 1,258.4132 pence per share.
- Confirm the updated total share capital and Treasury share count (74,708,000) in subsequent filings.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe) hold indirect interests in shares held by the GSK Trust.
- Recognize that this filing is a disclosure of corporate action and does not contain quarterly or annual financial performance data.